The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Highlights Testing Standards in Patients With Colorectal Cancer

Scott Kopetz, MD
Published Online:6:24 PM, Mon May 14, 2018


Scott Kopetz, MD, associate professor of GI Medical Oncology at MD Anderson Center, advises community oncologists on what testing should be done for patients with colorectal cancer (CRC).

Updated guidelines suggest microsatellite testing (MSI) for every patient with CRC regardless of their stage. This will help in discovering the available novel therapies for your patient, Kopetz said. Other testing for this patient population should include KRAS, NRAS, and BRAF, which is currently considered a standard in this field.

More recently, some centers have begun to do hormone epidermal growth factor receptor 2 (HER2) amplifications in their patients with CRC, which has predictive and prognostic benefits. Kopetz believes this type of testing will begin appearing in guidelines in the future.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.